免疫共抑制受体在甲状腺髓样癌中的表达与预后价值
该研究在200例初治手术的甲状腺髓样癌(MTC)患者中,用组织芯片免疫组化评估PD-1、CTLA-4、TIM-3、LAG-3和TIGIT表达,并结合既往PD-L1结果回顾分析临床病理与预后相关性。TIM-3、CTLA-4表达及PD-1/PD-L1共表达与更差的结构性无复发生存相关,部分晚期MTC可能具有免疫原性。
要点
- TIM-3、PD-1、CTLA-4、LAG-3、TIGIT阳性率分别为48.0%、13.5%、12.5%、3.0%、3.0%。
- TIM-3、CTLA-4表达及PD-1/PD-L1共表达与更差的结构性无复发生存相关。
- 20例随访进展患者中12例TIM-3阳性,其中6例伴PD-1/PD-L1/CTLA-4中强表达。
核心结论
- TIM-3、CTLA-4表达及PD-1/PD-L1共表达是MTC肿瘤复发的潜在生物标志物。
- 部分晚期MTC可能具有免疫原性,单用或联合阻断TIM-3、PD-1、PD-L1或CTLA-4可能是未来潜在治疗方向。
研究设计与样本
- 回顾性分析200例在本院接受初始手术的MTC患者,采用组织芯片(TMA)进行免疫组化评估CIR表达。
- 结合既往PD-L1研究结果,分析这些蛋白与临床病理及预后的相关性。
主要发现
- TIM-3、PD-1、CTLA-4、LAG-3、TIGIT阳性分别见于96例(48.0%)、27例(13.5%)、25例(12.5%)、6例(3.0%)、6例(3.0%)患者。
- TIM-3、PD-1和CTLA-4表达呈正相关。
- Log-rank检验和多因素Cox分析均提示TIM-3、CTLA-4表达及PD-1/PD-L1共表达与更差的结构性无复发生存相关。
- 随访期间20例进展为晚期疾病,其中12例(60%)TIM-3阳性,6例同时伴中度至强PD-1、PD-L1或CTLA-4表达。
临床怎么用
- 对MTC患者可考虑检测TIM-3、CTLA-4及PD-1/PD-L1共表达以辅助评估复发风险。
- 晚期MTC中TIM-3阳性或PD-1/PD-L1/CTLA-4中强表达者可能从相应免疫检查点阻断中获益。
局限性
- 回顾性单中心研究,结论需外部验证。
- 免疫组化表达与临床预后相关,但未报告治疗干预结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Programmed cell death protein-1 (PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), lymphocyte activation gene-3 (LAG-3), and T-cell immunoglobulin and ITIM domain (TIGIT) are considered major immune co-inhibitory receptors (CIRs) and the most promising immunotherapeutic targets in cancer treatment, but they are largely unexplored in medullary thyroid carcinoma (MTC). OBJECTIVE: We aimed to provide the first evidence regarding the expression profiles and clinical significance of CIRs in a large cohort of MTC patients. DESIGN AND PATIENTS: In total, 200 MTC patients who received initial surgery in our hospital were included. Immunohistochemistry was performed to evaluate CIR expressions in tissue microarrays (TMAs). Combined with the results of our previous programmed cell death ligand-1 (PD-L1) study, clinicopathologic and prognostic correlations of these proteins were retrospectively analyzed. RESULTS: TIM-3, PD-1, CTLA-4, LAG-3, and TIGIT positivity was detected in 96 (48.0%), 27 (13.5%), 25 (12.5%), 6 (3.0%), and 6 (3.0%) patients, respectively, in whom TIM-3, PD-1, and CTLA-4 expressions were positively correlated. Log-rank tests and multivariate Cox analyses both indicated that TIM-3, CTLA-4 expression, and PD-1/PD-L1 coexpression were associated with worse structural recurrence-free survival. In addition, among 20 patients who developed advanced disease during follow-up, 12 (60%) showed TIM-3 positivity, among whom 6 cases also had concurrent moderate to strong PD-1, PD-L1, or CTLA-4 expression. CONCLUSIONS: Using the currently largest TMA cohort of this rare cancer, we delineated the CIR expression profiles in MTC, and identified TIM-3, CTLA-4 expression, and PD-1/PD-L1 coexpression as promising biomarkers for tumor recurrence. Furthermore, a subset of advanced MTCs are probably immunogenic, for which single or combined immunotherapy including TIM-3, PD-1, PD-L1, or CTLA-4 blockade may be potential therapeutic approaches in the future.
引用
- Shi X, Li CW, Tan LC, et al. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study. J Clin Endocrinol Metab. 2021. PMID: 33000173. doi:10.1210/clinem/dgaa701
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。